Nakao Shu, Ihara Dai, Hasegawa Koji, Kawamura Teruhisa
Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Japan.
Global Innovation Research Organization, Ritsumeikan University, Kusatsu, Japan.
Eur Cardiol. 2020 Feb 26;15:1-10. doi: 10.15420/ecr.2019.03. eCollection 2020 Feb.
Induced pluripotent stem cells (iPSCs) are derived from reprogrammed somatic cells by the introduction of defined transcription factors. They are characterised by a capacity for self-renewal and pluripotency. Human (h)iPSCs are expected to be used extensively for disease modelling, drug screening and regenerative medicine. Obtaining cardiac tissue from patients with mutations for genetic studies and functional analyses is a highly invasive procedure. In contrast, disease-specific hiPSCs are derived from the somatic cells of patients with specific genetic mutations responsible for disease phenotypes. These disease-specific hiPSCs are a better tool for studies of the pathophysiology and cellular responses to therapeutic agents. This article focuses on the current understanding, limitations and future direction of disease-specific hiPSC-derived cardiomyocytes for further applications.
诱导多能干细胞（iPSC）是通过导入特定转录因子对体细胞进行重编程而获得的。它们具有自我更新能力和多能性。人（h）iPSC有望广泛应用于疾病建模、药物筛选和再生医学。从患有突变的患者身上获取心脏组织进行基因研究和功能分析是一种极具侵入性的操作。相比之下，疾病特异性hiPSC是从患有导致疾病表型的特定基因突变的患者体细胞中获得的。这些疾病特异性hiPSC是研究病理生理学和细胞对治疗药物反应的更好工具。本文重点关注疾病特异性hiPSC来源的心肌细胞在进一步应用方面的当前认识、局限性和未来方向。
